Zura Bio LTD 10-K annual reports

Annual reports — audited financials, the full risk-factor list, and management’s account of the year.

NASDAQ

19 Mar 2026

ZURA

10-K: Zura Bio Reports $68.7M Loss, Secures $135.1M in Equity

Zura Bio Limited, a clinical-stage biotechnology company, reported a net loss of $68.7 million for the fiscal year ended December 31, 2025, while successfully raising $135.1 million in a February 2026 equity offering to fund ongoing clinical trials.

NASDAQ

25 Mar 2025

ZURA

Zura Bio LTD

10-K: Zura Bio Limited Reports 2024 Financial Results, Highlights Clinical Development Progress

Zura Bio Limited details its financial performance for 2024 and provides updates on its clinical-stage immunology programs, including the initiation of a Phase 2 study for tibulizumab in systemic sclerosis.

NASDAQ

28 Mar 2024

ZURA

Zura Bio LTD

10-K: Zura Bio Details Share Structure and Warrant Terms in SEC Filing

Zura Bio Limited outlines its share capital, including Class A Ordinary Shares, preference shares, and details of outstanding warrants in a recent SEC filing.